Guggenheim Capital LLC Crinetics Pharmaceuticals, Inc. Transaction History
Guggenheim Capital LLC
- $13.9 Billion
- Q2 2024
A detailed history of Guggenheim Capital LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 28,449 shares of CRNX stock, worth $1.44 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
28,449
Previous 4,418
543.93%
Holding current value
$1.44 Million
Previous $206,000
518.45%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
244Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$316 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$310 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$234 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$229 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$224 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.73B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...